The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Acute Kidney Injury
Interventions
DRUG

Anticoagulation with nafamostat mesilate

Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.

Trial Locations (1)

120-752

Severance Hospital, Seoul

All Listed Sponsors
collaborator

SK Chemicals Co., Ltd.

INDUSTRY

lead

Yonsei University

OTHER

NCT01761994 - The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy | Biotech Hunter | Biotech Hunter